- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00217581
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with oxaliplatin and docetaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with oxaliplatin and docetaxel works in treating patients with locally advanced unresectable or metastatic stomach or gastroesophageal junction cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the time to progression in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma treated with bevacizumab, oxaliplatin, and docetaxel.
Secondary
- Determine the response rate in patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Determine time to treatment failure and overall survival of patients treated with this regimen.
- Determine the changes in general and disease-specific quality of life, in terms of response to treatment, in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 120 minutes, and docetaxel IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
After completion of study treatment, patients are followed periodically for up to 2 years.
PROJECTED ACCRUAL: A total of 38 patients will be accrued for this study within 18-23 months.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109-0942
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, Forente stater, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Forente stater, 48201
- Veterans Affairs Medical Center - Detroit
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210-1240
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed gastric or gastroesophageal junction adenocarcinoma
- Locally advanced unresectable or metastatic disease
Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10mm by spiral CT scan
- Bone metastases, ascites, or pleural effusions are not considered measurable disease
- Evaluable disease must be present outside previously irradiated field
- No CNS or brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- SWOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 10 mg/dL
- No evidence of bleeding diathesis or coagulopathy
Hepatic
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Bilirubin ≤ ULN
- INR < 1.5
Renal
- Creatinine < 2.0 mg/dL
- Urine protein:creatinine ratio < 1.0
Cardiovascular
- No history of deep venous thrombosis requiring anticoagulation
- No active angina
- No myocardial infarction within the past year
- No cerebrovascular accident within the past year
- No uncontrolled hypertension (systolic blood pressure [BP] > 170 mm Hg and/or diastolic BP > 100 mm Hg) despite medical management
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No peripheral neuropathy > grade 1
- No history of allergy to any of the study drugs or drugs formulated with polysorbate 80
- No known HIV infection
- No active peptic ulcer disease
- No serious non-healing wound, ulcer, or bone fracture
- No unresolved bacterial infection requiring antibiotics
- No other active malignancy within the past 3 years except for cancers that have been treated with a curative intent
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent immunotherapy
Chemotherapy
- No prior chemotherapy for gastric cancer unless disease relapsed > 6 months after completion of non-taxane adjuvant chemotherapy
- No other concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- At least 3 weeks since radiotherapy
Surgery
- At least 4 weeks since prior surgery or open biopsy (except indwelling venous catheter placement)
- No concurrent surgery
Other
- At least 4 weeks since prior and no concurrent participation in another experimental drug trial
- No concurrent full-dose anticoagulation
- No concurrent experimental drugs
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Docetaxel, Oxaliplatin & Bevacizumab
Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes.
If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes.
If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
|
Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes.
If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes.
If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
Andre navn:
Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70
mg/m(2), IV over 60 minutes, day 1 of each cycle;
Andre navn:
Must be administered 3rd after Bevacizumab and Docetaxel.
75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Time to Progression
Tidsramme: After every 2 cycles (1 cycle =21 days) From study registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
|
After every 2 cycles (1 cycle =21 days) From study registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Response Rate by RECIST Criteria
Tidsramme: After every 2 cycles (1 cycle =21 days)
|
Percentage of Participants with response by RECIST criteria until progression
|
After every 2 cycles (1 cycle =21 days)
|
Toxicity Profile
Tidsramme: At 21 days following completion of study treatment
|
Toxicity profile of grade 3 and grade 4 events using the NCI-CTCAE Version 3.0 scale for toxicity grading.
|
At 21 days following completion of study treatment
|
Time to Treatment Failure
Tidsramme: Every 21 days From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Time to treatment failure using the Kaplan-Meier method
|
Every 21 days From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Overall Survival
Tidsramme: Patients will be followed for survival every three months after they are off study or until their disease progresses, for up to two years
|
Overall survival using the Kaplan-Meier method
|
Patients will be followed for survival every three months after they are off study or until their disease progresses, for up to two years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Philip A. Philip, MD, PhD, FRCP, Barbara Ann Karmanos Cancer Institute
- Hovedetterforsker: Basil El-Rayes, MD, Barbara Ann Karmanos Cancer Institute
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Neoplasmer i hode og nakke
- Esophageal sykdommer
- Neoplasmer i magen
- Neoplasmer i spiserøret
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, immunologiske
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Docetaxel
- Oksaliplatin
- Bevacizumab
Andre studie-ID-numre
- CDR0000441641
- P30CA022453 (U.S. NIH-stipend/kontrakt)
- WSU-D-2840
- UMCC-2005-052
- AVENTIS-WSU-D-2840
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Magekreft
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertical Sleeve Gastrectomy | Magebånd | Bypass, GastricForente stater
-
Medtronic - MITGFullført
-
North Dakota State UniversityNational Institutes of Health (NIH)FullførtRoux en Y Gastric Bypass kirurgiForente stater
-
DuomedAktiv, ikke rekrutterendeOvervekt | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgia
-
Olympus Corporation of the AmericasUnity Health TorontoFullført
-
Wageningen UniversityRijnstate HospitalUkjentRoux-en-Y Gastric BypassNederland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtRoux en Y Gastric BypassForente stater
-
Rijnstate HospitalFullførtRoux-en-Y Gastric Bypass | Magetømming | Bariatrisk kirurgiNederland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtSleeve Gastrectomy | Roux en Y Gastric BypassForente stater
-
Rijnstate HospitalFullførtBariatrisk kirurgi | Jern absorpsjon | Roux- en -y Gastric BypassNederland
Kliniske studier på Bevacizumab
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Klarcellet ovariecystadenokarsinom | Endometrioid adenokarsinom på eggstokkene | Serøst cystadenokarsinom på eggstokkene | Endometrie klarcellet adenokarsinom | Endometrial serøst adenokarsinom og andre forholdForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutteringTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Endometrioid adenokarsinom på eggstokkene | Klarcellet adenokarsinom i eggstokkene | Adenokarsinom i egglederen | Serøst adenokarsinom i egglederen | Serøst adenokarsinom på eggstokkene | E... og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stage IVA Livmorhalskreft AJCC v6 og v7 | Tilbakevendende livmorhalskreft | Stadium IV Livmorhalskreft AJCC v6 og v7 | Stadium IVB Livmorhalskreft AJCC v6 og v7Forente stater
-
National Cancer Institute (NCI)NRG OncologyFullførtBevacizumab med eller uten trebananib ved behandling av pasienter med tilbakevendende hjernesvulsterGlioblastom | Gliosarkom | Tilbakevendende glioblastom | Oligodendrogliom | Kjempecelleglioblastom | Tilbakevendende hjerneneoplasmaForente stater, Canada
-
M.D. Anderson Cancer CenterRekrutteringStage IB hepatocellulært karsinom AJCC v8 | Stage II hepatocellulært karsinom AJCC v8 | Resektabelt hepatocellulært karsinom | Stage I hepatocellulært karsinom AJCC v8 | Stage IA hepatocellulært karsinom AJCC v8Forente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IV kutant melanom AJCC v6 og v7 | Stage IIIC kutant melanom AJCC v7 | Uopererbart melanomForente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeEndometrioid adenokarsinom på eggstokkene | Primært peritonealt høygradig serøst adenokarsinom | Endometrioid adenokarsinom i egglederen | Platina-resistent egglederkarsinom | Platina-resistent primært peritonealt karsinom | Ovarial høygradig serøst adenokarsinom | Platina-resistent ovariekarsinom | Eggleder...Forente stater, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk lunge ikke-småcellet karsinom | Stage IVA lungekreft AJCC v8 | Stage IVB lungekreft AJCC v8 | Stadium III lungekreft AJCC v8 | Stadium IV lungekreft AJCC v8 | Stadium IIIA lungekreft AJCC v8 | Stadium IIIB lungekreft AJCC v8 | Stadium IIIC lungekreft AJCC v8 | Lokalt avansert ikke-småcellet... og andre forholdForente stater
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeOndartet fast neoplasma | Endometrioid adenokarsinom på eggstokkene | Ovarialt udifferensiert karsinom | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Ondartet peritoneal neoplasma | Endometrie klarcellet adenokarsinom | Endometrial Endometrioid Adenocarcinoma | Endometrie blandet celle adenokarsinom og andre forholdForente stater
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsFullførtTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Platina-resistent egglederkarsinom | Platina-resistent primært peritonealt karsinom | Platina-resistent ovariekarsinom | Ildfast ovariekarsinom | Ildfast egglederkarsinom | Refraktært primært...Forente stater